Min menu


Latest News

The FDA agrees to store the Pfizer vaccine for Corona at -13 instead of -70 Celsius

The US Food and Drug Administration has approved the FDA to store and transport the Coronavirus vaccine developed by Pfizer and its German partner Biontech in standard freezing temperatures for up to two weeks in place of extremely cold conditions.

According to a report by the British newspaper "Daily Mail" last week, companies asked the health regulator in the United States to reduce the requirements for storing the Coronavirus vaccine at very low temperatures, which could allow it to be kept in pharmacy freezers. It can now be stored at a temperature ranging from - 13 degrees Fahrenheit to 5 degrees Fahrenheit for up to two weeks, according to new FDA directives.

"The alternative temperature for transportation and storage will help ease the burden of purchasing ultra-low cold storage equipment for vaccination sites and should help deliver the vaccine to more sites," said Peter Marks, director of the Food and Drug Administration's Center for Biological Assessment and Research.

In December, the US Food and Drug Administration granted emergency use permission for the vaccine and the current label to be stored at temperatures between -80 ° C and -60 ° C, which means they must be shipped in specially designed containers, but cold chain requirements have made pharmacists and shippers on Stand ready about safely storing accurate and valuable vaccine doses.

For its part, BioNTech said it imposed long-term storage and transportation requirements of -70 degrees out of caution because it began stability and durability tests on its vaccine relatively late.

While Pfizer and Biontech announced that they are planning to study the effects of a third dose of the Corona vaccine as a booster dose to confront new strains of the virus, as the two companies are scheduled to conduct experiments on participants from their original clinical experience.

According to the "Insider" site, the two companies will provide booster doses for up to 144 participants from 6 to 12 months after they receive the second dose of the vaccine.

The Phase 1 trial began in May 2020, so some people who participated already qualified for their third dose.

Tucson Company Inc
Tucson Company Inc
Tucson Company Inc It is one of the best Egyptian companies specialized in the field of creating and developing Android applications and games, selling them to others, and publishing them through all the services of publishing free and paid applications and games